PriceTargets.com logo

Asensus Surgical - ASXC Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $1.50
  • Forecasted Upside: 455.56%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.27 As of 09/29/2023 01:00 AM ET
▼ -0.01 (-3.57%)

This chart shows the closing price for ASXC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Asensus Surgical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASXC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASXC

Analyst Price Target is $1.50
▲ +455.56% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Asensus Surgical in the last 3 months. The average price target is $1.50, with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 455.56% upside from the last price of $0.27.

This chart shows the closing price for ASXC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Asensus Surgical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/3/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$1.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$2.00
5/12/2023Cantor FitzgeraldLower Target$1.50 ➝ $1.30
3/6/2023HC WainwrightLower TargetBuy$3.00 ➝ $2.00
2/22/2023HC WainwrightReiterated RatingBuy$3.00
1/10/2023HC WainwrightReiterated RatingBuy$3.00
9/8/2022Cantor FitzgeraldInitiated CoverageOverweight$1.50
8/10/2022HC WainwrightLower TargetBuy$4.00 ➝ $3.00
5/26/2021HC WainwrightInitiated CoverageBuy$4.00
3/16/2021Raymond JamesReiterated RatingHold
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/4/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Asensus Surgical logo
Asensus Surgical, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to pioneer a new era of Performance-Guided surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. The company's products include Senhance Surgical system, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures. Its products also comprise instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.
Read More

Today's Range

Now: $0.27
Low: $0.27
High: $0.29

50 Day Range

MA: N/A

52 Week Range

Now: $0.27
Low: $0.25
High: $1.18

Volume

736,201 shs

Average Volume

4,444,858 shs

Market Capitalization

$71.25 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Asensus Surgical?

The following equities research analysts have issued reports on Asensus Surgical in the last twelve months: Cantor Fitzgerald, and HC Wainwright.
View the latest analyst ratings for ASXC.

What is the current price target for Asensus Surgical?

2 Wall Street analysts have set twelve-month price targets for Asensus Surgical in the last year. Their average twelve-month price target is $1.50, suggesting a possible upside of 455.6%. HC Wainwright has the highest price target set, predicting ASXC will reach $2.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $1.00 for Asensus Surgical in the next year.
View the latest price targets for ASXC.

What is the current consensus analyst rating for Asensus Surgical?

Asensus Surgical currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ASXC will outperform the market and that investors should add to their positions of Asensus Surgical.
View the latest ratings for ASXC.

What other companies compete with Asensus Surgical?

Other companies that are similar to Asensus Surgical include T2 Biosystems, BrainsWay, Lucid Diagnostics, Delcath Systems and InspireMD. Learn More about companies similar to Asensus Surgical.

How do I contact Asensus Surgical's investor relations team?

Asensus Surgical's physical mailing address is 1 Tw Alexander Drive, Durham, North Carolina 27703. The company's listed phone number is (919) 765-8400 and its investor relations email address is invest@transenterix.com. The official website for Asensus Surgical is www.asensus.com. Learn More about contacing Asensus Surgical investor relations.